Literature DB >> 16306790

Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.

Russell Vang1, Allen M Gown, Todd S Barry, Darren T Wheeler, Brigitte M Ronnett.   

Abstract

Ovarian atypical proliferative (borderline) mucinous tumors of gastrointestinal and seromucinous types are considered subtypes within the mucinous tumor category despite the presence of distinctive clinicopathologic features that seromucinous tumors share with pure serous tumors. Immunophenotypic differences have not been extensively investigated. Immunohistochemical studies were performed to compare the expression patterns of cytokeratins 7 and 20 (CK7, CK 20), estrogen and progesterone receptors (ER, PR), CA-125, mesothelin, and WT-1 in 28 tumors of gastrointestinal type and 12 tumors of seromucinous type. Both gastrointestinal and seromucinous type tumors had a high frequency of CK7 expression (93% and 100%, respectively). The gastrointestinal type tumors were characterized by frequent expression of CK20 (86%) and CDX2 (39%), infrequent expression of CA-125 (11%) and mesothelin (7%), and lack of expression of ER, PR, and WT-1. In contrast, the seromucinous type tumors were characterized by frequent expression of ER (100%), PR (67%), CA-125 (92%), and mesothelin (83%), infrequent expression of WT-1 (8%), and lack of expression of CK20 and CDX2. The gastrointestinal and seromucinous types of atypical proliferative mucinous tumors are immunophenotypically distinctive tumors. The former are characterized by expression of markers of gastrointestinal-type differentiation (CK20 and CDX2), whereas the latter are characterized by expression of "müllerian-type" markers (ER, PR, CA-125, and mesothelin). Expression of the latter markers in the seromucinous tumors, which also are expressed in pure serous tumors, and lack of expression of gastrointestinal-type markers, combined with the clinicopathologic features these tumors share with pure serous tumors, support the concept that this subtype is more closely related to serous than gastrointestinal type mucinous tumors and justify the designation "seromucinous."

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16306790     DOI: 10.1097/01.pgp.0000177125.31046.fd

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  16 in total

1.  Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.

Authors:  Taira Hada; Morikazu Miyamoto; Hiroki Ishibashi; Haruka Kawauchi; Hiroaki Soyama; Hiroko Matsuura; Takahiro Sakamoto; Soichiro Kakimoto; Tadashi Aoyama; Hideki Iwahashi; Rie Suzuki; Hitoshi Tsuda; Masashi Takano
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

Review 3.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

4.  Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.

Authors:  Chen Hsuan Wu; Tsui-Lien Mao; Russell Vang; Ayse Ayhan; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2012-07       Impact factor: 2.762

5.  Mucinous borderline ovarian tumors: pathological and prognostic study at Salah Azaiez Institute.

Authors:  Ghada Sahraoui; Asma Fitouri; Lamia Charfi; Maha Driss; Maher Slimane; Monia Hechiche; Karima Mrad; Raoudha Doghri
Journal:  Pan Afr Med J       Date:  2022-04-29

Review 6.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

7.  Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.

Authors:  Vincenzo Ciocca; Alessandro Bombonati; Juan P Palazzo; Stephanie Schulz; Scott A Waldman
Journal:  Histopathology       Date:  2009-08       Impact factor: 5.087

Review 8.  Seromucinous Tumors of the Ovary. What's in a Name?

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2016-01       Impact factor: 2.762

9.  Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.

Authors:  Eriko Nakamura; Yuichiro Sato; Sayaka Moriguchi; Atsushi Yamashita; Takashi Higo; Yujiro Asada
Journal:  Case Rep Obstet Gynecol       Date:  2015-05-13

Review 10.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.